Skip to main content

Dyne Therapeutics, Inc.

DYN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001818794

In the last 90 days, Dyne Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 245 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Dyne Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
10 filings
6 insiders, $90.2M in total
Insiders trading
6
Net value
−$90.2M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Dyne Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Dyne Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Friedl-Naderer JohannaChief Commercial Officer152,897Sep 8, 20267
Kerr DouglasChief Medical Officer162,564Sep 8, 20267
Cox JohnCEO & President357,507Sep 8, 20267
Rhodes Jason PDirector428,946IndirectAug 17, 20269
Lucera ErickChief Financial Officer119,766Aug 17, 20265
Kersten DirkDirector3,586,796IndirectJul 29, 20269
Greene Barry EDirector–Jun 23, 20261
Hurwitz EdwardDirector–Jun 9, 20261
Posner Brian SDirector24,500Jun 9, 20268
Lubner David CharlesDirector0Jun 9, 20262
Stehman-Breen CatherineDirector–Jun 9, 20261
Incerti CarloDirector0Jun 9, 20261
Karnani VikramDirector–Dec 23, 20251
Scalzo Richard WilliamSVP, Head of Finance & Admin.122,330Mar 13, 20250
Beskrovnaya OxanaChief Scientific Officer195,840Mar 13, 20250
High Susanna GattiChief Operating Officer131,636Sep 19, 20240
McNeill JonathanChief Business Officer132,106Aug 20, 20240
Farwell WildonChief Medical Officer143,222Aug 20, 20240
Brumm Joshua TCEO & President537,998Mar 12, 20240
Atlas Venture Opportunity Fund I, L.P.10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity I, L.P.10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity I, LLC10% Owner847,388IndirectMar 5, 20240
Atlas Venture Opportunity Fund II, L.P.10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity II, LLC10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity II, LP10% Owner847,388IndirectMar 5, 20240
Atlas Venture Fund XI, L.P.10% Owner864,487IndirectFeb 28, 20240
Atlas Venture Associates XI, LLC10% Owner864,487IndirectFeb 28, 20240
Atlas Venture Associates XI, L.P.10% Owner864,487IndirectFeb 28, 20240
Klein Lawrence OttoDirector–Jul 6, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 6, 2025 (view filing)Jun 51 dayKerr DouglasChief Medical OfficerSSale−1.34K$13.35−$17.9K−1.4%92.8K after10b5-1
Jun 6, 2025 (view filing)Jun 51 dayFriedl-Naderer JohannaChief Commercial OfficerSSale−146$13.35−$1.95K−0.2%95.9K after10b5-1
Mar 13, 2025 (view filing)Mar 13Same dayFriedl-Naderer JohannaChief Commercial OfficerSSale−143$12.12−$1.73K−0.1%96.1K after10b5-1
Mar 13, 2025 (view filing)Mar 112 daysScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−1.34K$11.38−$15.3K−1.1%122.3K after10b5-1
Mar 13, 2025 (view filing)Mar 112 daysBeskrovnaya OxanaChief Scientific OfficerSSale−2.15K$11.38−$24.5K−1.1%195.8K after10b5-1
Mar 7, 2025 (view filing)Mar 52 daysKerr DouglasChief Medical OfficerSSale−1.34K$11.83−$15.9K−1.4%94.2K after10b5-1
Mar 7, 2025 (view filing)Mar 52 daysCox JohnCEO & PresidentSSale−4.06K$11.83−$48.0K−2.7%146.2K after10b5-1
Mar 7, 2025 (view filing)Mar 52 daysScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−917$11.83−$10.8K−0.7%123.7K after10b5-1
Mar 7, 2025 (view filing)Mar 52 daysBeskrovnaya OxanaChief Scientific OfficerSSale−1.09K$11.83−$12.9K−0.5%198.0K after10b5-1
Feb 25, 2025 (view filing)Feb 187 daysLateBeskrovnaya OxanaChief Scientific OfficerSSale−2.60K$13.95−$36.2K−1.3%199.1K after10b5-1
Feb 18, 2025 (view filing)Feb 18Same dayScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−2.49K$13.95−$34.7K−2.0%124.6K after10b5-1
Dec 11, 2024 (view filing)Dec 11Same dayBeskrovnaya OxanaChief Scientific OfficerSSale−2.33K$28.12−$65.6K−1.1%201.7K after10b5-1
Dec 11, 2024 (view filing)Dec 11Same dayScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−1.46K$28.12−$40.9K−1.1%127.1K after10b5-1
Dec 10, 2024 (view filing)Dec 6-94 daysKersten DirkDirectorSSale−136.1K$29.30−$3.99M−2.5%5.40M after2 lots
Dec 6, 2024 (view filing)Dec 4-52 daysKersten DirkDirectorSSale−138.8K$29.38−$4.08M−2.4%5.54M after2 lots
Dec 4, 2024 (view filing)Dec 2-32 daysKersten DirkDirectorSSale−110.9K$29.50−$3.27M−1.9%5.68M after3 lots
Nov 18, 2024 (view filing)Nov 144 daysRhodes Jason PDirectorSSale−782$33.10−$25.9K−0.1%847.3K after4 lots
Nov 18, 2024 (view filing)Nov 18Same dayIncerti CarloDirectorSSale−16.5K$28.73−$474.0K−100.0%0 after
Nov 18, 2024 (view filing)Nov 18Same dayScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−2.73K$28.20−$77.1K−2.8%95.8K after10b5-1
Nov 18, 2024 (view filing)Nov 18Same dayBeskrovnaya OxanaChief Scientific OfficerSSale−2.86K$28.20−$80.5K−2.0%137.5K after10b5-1
Nov 15, 2024 (view filing)Nov 13-142 daysKersten DirkDirectorSSale−19.7K$34.14−$673.7K−0.3%5.79M after2 lots10b5-1
Oct 22, 2024 (view filing)Oct 18-214 daysKersten DirkDirectorSSale−13.5K$35.16−$475.9K−15.6%73.1K after2 lots10b5-1
Oct 18, 2024 (view filing)Oct 16-172 daysKersten DirkDirectorSSale−36.7K$35.29−$1.29M−29.7%86.6K after2 lots10b5-1
Oct 7, 2024 (view filing)Oct 34 daysKersten DirkDirectorSSale−5.44K$35.13−$191.1K−4.2%123.3K after10b5-1
Oct 3, 2024 (view filing)Oct 1-22 daysKersten DirkDirectorSSale−29.9K$35.32−$1.06M−18.9%128.8K after2 lots10b5-1
Oct 1, 2024 (view filing)Sep 27-304 daysKersten DirkDirectorSSale−31.0K$35.50−$1.10M−16.3%158.7K after3 lots10b5-1
Sep 27, 2024 (view filing)Sep 25-262 daysKersten DirkDirectorSSale−3.62K$35.14−$127.1K−1.9%189.7K after2 lots10b5-1
Sep 24, 2024 (view filing)Sep 20-234 daysKersten DirkDirectorSSale−120.2K$36.07−$4.34M−38.4%193.3K after4 lots10b5-1
Sep 20, 2024 (view filing)Sep 18-192 daysKersten DirkDirectorSSale−80.3K$36.15−$2.90M−20.4%313.5K after3 lots10b5-1
Sep 19, 2024 (view filing)Sep 181 dayHigh Susanna GattiChief Operating OfficerSSale−8.98K$34.41−$308.9K−6.4%131.6K after2 lots10b5-1
Sep 19, 2024 (view filing)Sep 181 dayScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−1.39K$34.55−$48.0K−1.4%98.6K after10b5-1
Sep 19, 2024 (view filing)Sep 181 dayBeskrovnaya OxanaChief Scientific OfficerSSale−2.34K$34.55−$80.8K−1.6%140.4K after10b5-1
Sep 18, 2024 (view filing)Sep 16-172 daysKersten DirkDirectorSSale−4.59K$35.10−$161.2K−1.2%393.8K after2 lots10b5-1
Sep 11, 2024 (view filing)Sep 11Same dayBeskrovnaya OxanaChief Scientific OfficerSSale−2.16K$31.89−$68.9K−1.5%142.7K after10b5-1
Sep 11, 2024 (view filing)Sep 11Same dayScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−1.47K$31.89−$46.8K−1.4%100.0K after10b5-1
Sep 11, 2024 (view filing)Sep 11Same dayHigh Susanna GattiChief Operating OfficerSSale−5.27K$31.89−$168.1K−3.6%140.6K after2 lots10b5-1
Sep 10, 2024 (view filing)Sep 64 daysScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−126.1K$32.15−$4.05M−55.4%101.4K after2 lots
Sep 9, 2024 (view filing)Sep 54 daysKersten DirkDirectorSSale−1.58K$35.03−$55.2K−0.4%398.4K after10b5-1
Sep 4, 2024 (view filing)Sep 4Same dayCox JohnCEO & PresidentPPurchase+32.0K$33.04+$1.06MNew position8.00K after8 lots
Sep 4, 2024 (view filing)Aug 305 daysKersten DirkDirectorSSale−31.3K$45.59−$1.43M−7.3%400.0K after2 lots10b5-1
Aug 30, 2024 (view filing)Aug 28-292 daysKersten DirkDirectorSSale−134.3K$45.03−$6.05M−23.7%431.3K after4 lots10b5-1
Aug 28, 2024 (view filing)Aug 26-272 daysKersten DirkDirectorSSale−154.9K$44.87−$6.95M−21.5%565.6K after3 lots10b5-1
Aug 26, 2024 (view filing)Aug 22-234 daysKersten DirkDirectorSSale−180.4K$46.02−$8.30M−20.0%720.5K after4 lots10b5-1
Aug 22, 2024 (view filing)Aug 20-212 daysKersten DirkDirectorSSale−222.6K$46.61−$10.4M−19.8%900.9K after5 lots10b5-1
Aug 20, 2024 (view filing)Aug 191 dayScalzo Richard WilliamSVP, Head of Finance & Admin.SSale−2.75K$45.12−$124.2K−2.4%111.0K after2 lots10b5-1
Aug 20, 2024 (view filing)Aug 191 dayMcNeill JonathanChief Business OfficerSSale−2.71K$45.12−$122.1K−2.0%132.1K after2 lots10b5-1
Aug 20, 2024 (view filing)Aug 191 dayFarwell WildonChief Medical OfficerSSale−2.32K$45.12−$104.7K−1.6%143.2K after2 lots10b5-1
Aug 20, 2024 (view filing)Aug 191 dayHigh Susanna GattiChief Operating OfficerSSale−2.91K$45.12−$131.3K−2.0%145.9K after2 lots10b5-1
Aug 20, 2024 (view filing)Aug 191 dayBeskrovnaya OxanaChief Scientific OfficerSSale−2.64K$45.12−$118.9K−1.8%144.9K after2 lots10b5-1
Aug 20, 2024 (view filing)Aug 16-194 daysKersten DirkDirectorSSale−248.7K$45.48−$11.3M−18.1%1.12M after6 lots10b5-1